March 2024 |
Notification regarding unquoted securities - EMR |
(26 March)
|
March 2024 |
Third Supplementary Target's Statement |
(21 March)
|
March 2024 |
Change in substantial holding |
(20 March)
|
March 2024 |
Third Supplementary Bidder's Statement |
(20 March)
|
March 2024 |
New High Grade Gold Discovery - Freeman's Find Prospect |
(18 March)
|
March 2024 |
Recommended and Unconditional Takeover Offer Extended |
(15 March)
|
March 2024 |
Application for quotation of securities - EMR |
(12 March)
|
March 2024 |
Option Exercise |
(12 March)
|
March 2024 |
Proposed issue of securities - EMR |
(04 March)
|
March 2024 |
Change in substantial holding |
(04 March)
|
March 2024 |
Notification regarding unquoted securities - EMR |
(04 March)
|
March 2024 |
Change in substantial holding |
(04 March)
|
March 2024 |
Final Director's Interest Notice |
(01 March)
|
March 2024 |
Board and Sub-Committee Changes |
(01 March)
|
February 2024 |
Emerald's Growth Strategy Underpinned by Okvau Excellence |
(29 February)
|
February 2024 |
Half Yearly Report and Accounts |
(29 February)
|
February 2024 |
Recommended and Unconditional Takeover Offer Extended |
(20 February)
|
February 2024 |
Second Supplementary Target's Statement |
(15 February)
|
February 2024 |
Application for quotation of securities - EMR |
(09 February)
|
February 2024 |
Option Exercise |
(09 February)
|
February 2024 |
Application for quotation of securities - EMR |
(09 February)
|
February 2024 |
Application for quotation of securities - EMR |
(01 February)
|
February 2024 |
Option Exercise |
(01 February)
|
January 2024 |
Quarterly Report |
(30 January)
|
January 2024 |
Recommended and Unconditional Takeover Offer Extended |
(25 January)
|
January 2024 |
Significant Exploration Results Continue at EMR Prospects |
(24 January)
|
January 2024 |
Application for quotation of securities - EMR |
(19 January)
|
January 2024 |
Application for quotation of securities - EMR |
(12 January)
|
January 2024 |
Another Impressive Quarter - Okvau Quarterly Gold Production |
(08 January)
|
January 2024 |
Application for quotation of securities - EMR |
(05 January)
|
December 2023 |
Application for quotation of securities - EMR |
(29 December)
|
December 2023 |
Recommended and Unconditional Takeover Offer Extended |
(29 December)
|
December 2023 |
Application for quotation of securities - EMR |
(22 December)
|
December 2023 |
Maiden Memot Gold Project Resource Statement |
(21 December)
|
December 2023 |
Application for quotation of securities - EMR |
(18 December)
|
December 2023 |
Option Exercise |
(18 December)
|
December 2023 |
Application for quotation of securities - EMR |
(18 December)
|
December 2023 |
Modern Slavery Statement |
(12 December)
|
December 2023 |
Application for quotation of securities - EMR |
(08 December)
|
December 2023 |
Change in substantial holding |
(07 December)
|
December 2023 |
Change of Director's Interest Notice |
(01 December)
|
December 2023 |
Option Exercise |
(01 December)
|
December 2023 |
Notification regarding unquoted securities - EMR |
(01 December)
|
December 2023 |
Application for quotation of securities - EMR |
(01 December)
|
December 2023 |
Application for quotation of securities - EMR |
(01 December)
|
November 2023 |
Chairman's Address - 2023 Annual General Meeting |
(29 November)
|
November 2023 |
Annual General Meeting Presentation |
(29 November)
|
November 2023 |
Results of Annual General Meeting |
(29 November)
|
November 2023 |
Option Exercise |
(24 November)
|
November 2023 |
Recommended and Unconditional Takeover Offer Extended |
(24 November)
|
November 2023 |
Application for quotation of securities - EMR |
(24 November)
|
November 2023 |
Application for quotation of securities - EMR |
(14 November)
|
November 2023 |
Option Exercise |
(14 November)
|
November 2023 |
Application for quotation of securities - EMR |
(13 November)
|
November 2023 |
Supplementary Target's Statement |
(09 November)
|
November 2023 |
Option Exercise |
(01 November)
|
November 2023 |
Second Supplementary Bidder's Statement |
(01 November)
|
November 2023 |
Application for quotation of securities - EMR |
(01 November)
|
October 2023 |
Quarterly Report |
(31 October)
|
October 2023 |
InvoCare Limited to be removed from the S&P/ASX 200 Index |
(31 October)
|
October 2023 |
Significant Exploration Results Continue at EMR Prospects |
(30 October)
|
October 2023 |
Recommended and Unconditional Takeover Offer Extended |
(27 October)
|
October 2023 |
Notice of Annual General Meeting/Proxy Form |
(26 October)
|
October 2023 |
Annual Report to shareholders |
(26 October)
|
October 2023 |
Letter to Shareholders - AGM Materials |
(26 October)
|
October 2023 |
Emerald Moves to 76.5% of Bullseye |
(13 October)
|
October 2023 |
Application for quotation of securities - EMR |
(13 October)
|
October 2023 |
Application for quotation of securities - EMR |
(10 October)
|
October 2023 |
Option Exercise |
(10 October)
|
October 2023 |
Recommended and Unconditional Takeover Offer for Bullseye |
(09 October)
|
October 2023 |
EMR Continues to Meet Guidance - Quarterly Gold Production |
(09 October)
|
October 2023 |
Recommended and Unconditional Takeover Offer Extended |
(06 October)
|
October 2023 |
TOV: Declaration of Unacceptable Circumstances and Orders |
(06 October)
|
October 2023 |
Date of Annual General Meeting |
(05 October)
|
October 2023 |
Proposed issue of securities - EMR |
(02 October)
|
October 2023 |
Notification regarding unquoted securities - EMR |
(02 October)
|
October 2023 |
ESOP Option Issue |
(02 October)
|